UK’s Trogenix raises £70m for cancer immunotherapy platform
Edinburgh, Scotland-based start-up Trogenix has raised £70 million ($95 million) for a pipeline of therapies for hard-to-treat aggressive cancer, starting with glioblastoma. The University of Edinburgh spinout, set up in early 2024 by investment group 4BIO Capital, has the bold ambition of transforming cancer therapy from chronic disease management to potentially curative one-time treatments. Its…